Drug Profile
Research programme: HIV-immunotherapeutic agents - Antigenics
Alternative Names: HSP-HIV vaccine; Therapeutic HSP-HIV vacineLatest Information Update: 14 Feb 2008
Price :
$50
*
At a glance
- Originator Antigenics
- Developer Antigenics; Massachusetts General Hospital
- Class
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 07 Aug 2006 No development reported - Preclinical for HIV-1 infections in USA (unspecified route)
- 26 Oct 2001 Preclinical development for HIV-1 infections in USA (Unknown route)